Dec 31, 2025 • Indian Pharma Post
BULLISH
Edgewise Therapeutics reports positive updates from HCM drug EDG-7500
Edgewise Therapeutics announced positive updates from its Phase 2 CIRRUS-HCM trial of EDG-7500, an oral cardiac sarcomere modulator for hypertrophic cardiomyopathy (HCM). The drug showed improvements in key HCM markers and maintained a strong safety profile, notably without affecting left ventricular ejection fraction (LVEF), differentiating it from cardiac myosin inhibitors. The company is advancing to Phase 3 development, with Part D of the trial focusing on dose optimization and biomarker-guided treatment.
Dec 26, 2025 • BioSpace
BULLISH
Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy
Edgewise Therapeutics announced the completion of Parts B and C and positive interim safety results from Part D of its Phase 2 CIRRUS-HCM trial for EDG-7500 in hypertrophic cardiomyopathy. The drug, a cardiac sarcomere modulator, was generally well tolerated with no clinically meaningful reductions in LVEF, differentiating it from existing therapies. The company is on track for full Part D data in Q2 2026 and Phase 3 initiation in Q4 2026.
Dec 25, 2025 • Yahoo Finance Singapore
NEUTRAL
Edgewise Therapeutics (EWTX): Assessing Valuation After an 80% Three-Month Surge in the Share Price
Edgewise Therapeutics (EWTX) has seen a significant surge, with its stock climbing 26% in one day and over 80% in the last three months, reaching a share price of $27.29. Despite this momentum, the company's price-to-book ratio of 5.2x suggests it is inexpensive compared to direct peers but elevated against the broader pharmaceuticals industry, indicating the market anticipates high future growth. Investors should consider potential clinical trial setbacks and the prolonged path to revenue for its pipeline drugs.
Dec 25, 2025 • Finviz
BULLISH
Why Edgewise Therapeutics Stock Rocked the Market Today
Edgewise Therapeutics (NASDAQ: EWTX) saw its stock surge nearly 26% after reporting positive interim data from its Phase 2 clinical trial of EDG-7500, a drug designed to treat hypertrophic cardiomyopathy (HCM). The trial showed clinical activity across significant HCM disease markers with a favorable safety profile. The company also announced that it has exceeded its year-end enrollment goal for the ongoing Part D of the trial.
Dec 25, 2025 • Sahm
SOMEWHAT-BULLISH
Why Is Edgewise Therapeutics Stock Soaring Wednesday?
Edgewise Therapeutics Inc. (NASDAQ: EWTX) stock soared on Wednesday after the company provided updates on its CIRRUS-HCM Phase 2 trial of EDG-7500, designed to treat hypertrophic cardiomyopathy (HCM). The trial showed clinical activity across key HCM markers with a favorable safety profile, and the company remains on track to deliver comprehensive efficacy and safety data in Q2 2026, advancing towards Phase 3 trial initiation by the end of 2026. This news comes shortly after its competitor, Cytokinetics, received FDA approval for their oHCM treatment, Myqorzo.
Dec 24, 2025 • ts2.tech
SOMEWHAT-BULLISH
Edgewise Therapeutics Stock (EWTX) Jumps on EDG-7500 CIRRUS-HCM Update: Dec. 24, 2025 News, Analyst Forecasts, and Key Catalysts
Edgewise Therapeutics (NASDAQ: EWTX) stock surged on December 24, 2025, after providing a positive update on its EDG-7500 investigational therapy for hypertrophic cardiomyopathy (HCM). The company announced favorable interim safety observations from Part D of its Phase 2 CIRRUS-HCM trial, specifically regarding left ventricular ejection fraction (LVEF) stability and arrhythmia monitoring. Despite one reported adverse event of new-onset atrial fibrillation (AF) deemed unrelated to the study drug, the update, occurring shortly after the FDA approval of a competitor's HCM therapy, was seen by many as a de-risking moment for Edgewise.